Prostate Cancer: What the Evidence Says About Risk, Detection, and Treatment

Advances in screening and imaging have reshaped how prostate cancer is detected and managed, but experts caution that early diagnosis still depends on informed, individualised decisions

Prostate cancer remains one of the most commonly diagnosed cancers among men worldwide, and global cancer registries have consistently ranked it among the leading causes of cancer diagnosis in men over the age of 50. Guidelines from the American Urological Association (AUA), the Society of Urologic Oncology (SUO), and the European Association of Urology (EAU) have all been revised in recent years to reflect a more nuanced, evidence-based approach to screening and treatment. This has meant more precise detection tools, greater emphasis on shared decision-making between doctor and patient, and a shift away from the one-size-fits-all model that once defined prostate cancer care. Increasingly, men are advised that decisions around testing and treatment should be made in consultation with specialists, and many patients begin this process by seeking out the best prostate cancer doctors available to them for an informed, individualised assessment. What follows is a review of what current research and clinical guidelines actually say.

What Is Prostate Cancer?

The prostate is a small gland, located below the bladder, that forms part of the male reproductive system. Prostate cancer develops when cells within this gland begin to grow and divide abnormally. Unlike many other cancers, prostate cancer often grows slowly, and a significant proportion of cases diagnosed in older men never go on to cause symptoms or become life-threatening. This distinction between slow-growing and aggressive disease is one of the central challenges in prostate cancer care, and it is the reason modern guidelines place such emphasis on distinguishing clinically significant cancer from indolent disease that may not require immediate treatment.

Who Is at Risk?

Research has identified several consistent risk factors for prostate cancer.

Age is the single strongest risk factor. Incidence rises sharply after age 50, and most diagnoses occur in men over 65.

Family history and genetics also play a substantial role. Men with a father or brother diagnosed with prostate cancer face a higher risk themselves, and inherited mutations in genes such as BRCA2 have been linked to a greater likelihood of developing more aggressive forms of the disease.

Race and ethnicity have also been shown, in large population studies, to influence both incidence and severity, with some groups facing a higher lifetime risk than others, though researchers continue to study the underlying biological and social factors behind this disparity.

Diet and lifestyle factors, including obesity, have been studied extensively, though the evidence connecting specific dietary patterns to prostate cancer risk is less definitive than the evidence for age and genetics.

Screening: A Preference-Sensitive Decision

For years, prostate cancer screening relied primarily on the prostate-specific antigen (PSA) blood test, often paired with a digital rectal examination. Current AUA/SUO guidelines, most recently updated in 2025, continue to recommend PSA-based screening, but with a critical qualification: screening should be undertaken through shared decision-making, meaning the doctor discusses the potential benefits and harms with the patient before proceeding, rather than ordering the test as a routine default. This reflects growing recognition that PSA elevation can result from causes other than cancer, including infection or benign prostate enlargement, and that not every elevated PSA level or diagnosed cancer requires immediate intervention.

Guidelines from the AUA and EAU generally support PSA-based screening at intervals tailored to individual risk, typically up to around age 70, with decisions beyond that age depending on a person’s overall health and life expectancy rather than age alone. Men with a family history of prostate cancer or known genetic risk factors are often advised to begin these conversations earlier than the general population.

When PSA levels or clinical findings raise concern, multiparametric MRI (mpMRI) of the prostate has become an increasingly important tool. It allows clinicians to visualise suspicious areas within the gland before deciding whether a biopsy is warranted, helping to reduce the number of unnecessary biopsies performed on men who do not have clinically significant disease.

Diagnosis and Grading

When a biopsy is performed, tissue samples are examined under a microscope and assigned a Gleason score, which is then translated into a Grade Group ranging from 1 to 5. This grading, combined with PSA level and clinical staging, allows doctors to categorise a diagnosis as low-, intermediate-, or high-risk. This risk stratification is central to modern prostate cancer care, since it directly informs whether a patient may be a candidate for active surveillance or requires more immediate treatment.

For men with low-risk, localised disease, guidelines increasingly support active surveillance, a structured approach involving regular PSA testing, periodic imaging, and repeat biopsies to monitor the cancer over time, rather than immediate surgery or radiation. This approach has gained support because research has shown that many low-risk prostate cancers can be safely monitored for years without progressing to a stage that threatens life.

Treatment Options

For men whose cancer is more advanced or aggressive, treatment decisions depend on the stage of disease, the patient’s age, overall health, and personal preferences. Established treatment options include:

Radical prostatectomy, the surgical removal of the prostate gland, performed through open, laparoscopic, or robot-assisted techniques.

Radiation therapy, delivered either externally or through brachytherapy, in which radioactive seeds are placed directly into the prostate.

Hormone therapy, which reduces levels of testosterone, a hormone that can fuel the growth of prostate cancer cells, and is often used for more advanced disease or in combination with radiation.

For cancer that has spread beyond the prostate, treatment may involve a combination of hormone therapy, chemotherapy, and newer targeted agents, an area of active clinical research that continues to evolve.

Guidelines from the AUA and the American Society for Radiation Oncology (ASTRO) also note that genetic and genomic testing can, in select cases, help refine risk stratification and guide treatment decisions, though this testing is not recommended as a routine step for every patient.

Living With Prostate Cancer

Because many prostate cancers are slow-growing and detected at an early stage, a large proportion of men diagnosed with the disease go on to live for many years, particularly when the cancer is localised to the prostate at the time of diagnosis. This has shifted part of the clinical conversation toward managing the long-term effects of treatment, including urinary, sexual, and bowel side effects, which can significantly affect quality of life and are now considered an essential part of counselling patients before they choose a treatment path.

The Way Forward

Clinical guidelines continue to evolve as research improves the tools available for detection and risk stratification. The growing use of mpMRI, more refined genetic risk assessment, and a firmer emphasis on shared decision-making all reflect a broader shift in how prostate cancer is approached: not as a disease to be tested for and treated uniformly, but as a condition whose management must be tailored to each patient’s specific risk profile, values, and circumstances. For men navigating a new diagnosis or considering whether to be screened at all, guidelines are unanimous on one point — this is a decision best made in careful consultation with a qualified specialist, based on individual risk rather than age or anxiety alone.